(Sharecast News) - EKF Diagnostics said in an update on Tuesday that trading so far in 2026 remained in line with management expectations, supported by strong cash generation and continued momentum in its hematology and life sciences businesses.
The AIM-listed diagnostics company, which was holding its annual general meeting, said the first year of its five-year strategic development plan had re-established the business with a simplified product offering, greater commercial focus on strategically important areas and an expanded marketing team to support organic growth.

Executive chair Julian Baines said operational cash generation remained "very strong", alongside continued internal investment for growth and the ongoing share buyback programme.

EKF had cash of £15.0m as of 8 May, including £2.1m held by its Russian subsidiary and subject to regulatory restrictions.

The company said commercial traction in hematology remained strong, with good ongoing instrument placements and increased consumables pull-through, as expected.

In life sciences, EKF said β-HB sales had performed ahead of management expectations, while the pipeline and prospects for contract fermentation services continued to grow and show steady improvement.

EKF said it remained on track to deliver revenue and adjusted EBITDA growth for the year ending 31 December 2026 in line with market expectations.

Management said consensus forecasts stood at revenue of £54.6m and adjusted EBITDA of £13.6m.

The company said it would provide an unaudited trading update for the first half of 2026 at the end of July.

At 1202 BST, shares in EKF Diagnostics Holdings were down 0.39% at 26.9p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

• News Channel